Lyell Immunopharma, Inc. (LYEL) Operating margin 2019–2025
Lyell Immunopharma, Inc. (LYEL) operating margin by fiscal year — reported operating income divided by reported revenue.
-748344.4%FY2025 · since FY2019: -15538.7% → -748344.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -748344.4% | -160221.5 pp |
| FY2024 | -588123.0% | -398116.8 pp |
| FY2023 | -190006.2% | -189785.3 pp |
| FY2022 | -220.9% | +1795.8 pp |
| FY2021 | -2016.7% | +715.9 pp |
| FY2020 | -2732.6% | +12806.1 pp |
| FY2019 | -15538.7% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice